
Annexon Investor Relations Material
Latest events

Study Result
Annexon
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Annexon Inc
Access all reports
Annexon, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company focuses on targeting C1q, an initiating molecule of the classical complement pathway, which plays a critical role in various disease processes, including antibody-mediated autoimmune diseases and complement-mediated neurodegeneration. Annexon's pipeline includes several product candidates such as ANX005, which is in clinical trials for Guillain-Barré syndrome, and other trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Annexon is headquartered in Brisbane, California, and its shares are listed on the Nasdaq.
Key slides for Annexon Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Annexon Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Annexon Inc
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
ANNX
Country
🇺🇸 United States